2170 Federal Register / Vol. 62, No. 10 / Wednesday, January 15, 1997 / Notices

DATES: Written proposals must be

received at the above address by 5:00

p.m. on March 17, 1996.

SUPPLEMENTARY INFORMATION: The NCI is

seeking a pharmaceutical or

biotechnology company which, after

obtaining a license in accordance with

the requirements of the regulations

governing the transfer of Governmentdeveloped rights, (37 CFR part 404), can

purify a recombinant CR–1 protein (for

which patents are pending or have been

issued) and utilize this purified

recombinant CR–1 protein as an

immunogen to generate a panel of

mouse monoclonal antibodies. The

immunoreactive CR–1 protein has been

detected by immunoperoxidase staining

using a rabbit anti-peptide polyclonal

CR–1 antibody in a majority of human

colon cancers, breast cancers, gastric

cancers, and pancreatic cancers. Little

or no staining was detected in

surrounding, noninvolved colon, breast

or gastric epithelial cells. In addition, a

majority of premalignant colonic

adenomas, breast ductal carcinomas in

situ and gastric intestinal metaplasia

express immunoreactive CR–1.

A recombinant CR–1 protein has been

generated using a baculovirus

expression vector in Sf-9 insect cells

and a partially purified protein

obtained. This protein as well as

synthetic, refolded peptides that

correspond to the EGF-like domain in

CR–1 are mitogenic for human breast

cancer cells and can modulate milk

protein expression, yet fail to bind to

the EGF receptor or other type I receptor

tyrosine kinases. Expression of CR–1

antisense mRNA using a recombinant,

replication defective retroviral

expression vector in colon cancer cells

that expresses CR–1 inhibits the growth

of these cells in vivo in nude mice. In

order to utilize diagnostic and

therapeutic potentials of CR–1, it will be

necessary to purify a significant amount

of the recombinant CR–1 protein to

more fully define its biological

properties and to identify the receptor

through which it functions. In addition,

mouse monoclonal antibodies against

the purified CR–1 recombinant protein

will expedite screening studies for CR–

1 expression in other human

premalignant lesions and cancers and

should exhibit more specificity and

sensitivity for the detection of CR–1 in

tissues by immunocytochemistry (ICC)

or in tissue extracts or serum samples by

ELISA.

The United States Public Health

Service owns the following issued

patents which may be relevant to the

subject technology:

1. United States Patent No. 5,264,557,

issued November 23, 1993, ‘‘Human

CRIPTO-Related Gene.’’

2. United States Patent No. 5,256,643,

issued October 26, 1993, ‘‘Cloned

Human CRIPTO Gene and Applications

Thereof.’’

Questions regarding licensing should

be directed to Joseph Hemby, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

#325, Rockville, MD 20852–3804,

telephone (301) 496–7056.

The role of the National Cancer

Institute, Division of Basic Sciences,

includes:

1. NCI will provide vectors that

encode CR–1 and can be used to

produce CR–1 in E. coli and in Sf-9

insect cells.

2. NCI will provide a rabbit

polyclonal anti-CR–1 antibody for

monitoring CR–1 recovery during the

purification from the yeast conditioned

medium.

3. NCI will assay the purified

recombinant CR–1 protein for

bioactivity.

4. NCI will screen anti-CR–1

monoclonal antibodies for reactivity by

Western blot analysis against native CR–

1 protein from CR–1 positive human

embryonal carcinoma or colon

carcinoma cells.

The role of the successful collaborator

will include:

1. Purify to homogeneity 30–50

milligrams of CR–1 from E. coli or Sf9 insect cell conditioned medium.

2. Provide the purified recombinant

CR–1 protein.

3. Utilize the purified recombinant

CR–1 protein to generate mouse antiCR–1 monoclonal antibodies.

4. Screen anti-CR–1 monoclonal

antibodies for specificity, reactivity, and

sensitivity towards the recombinant CR–

1 protein.

5. Ascertain whether monoclonal antiCR–1 antibodies can detect nature CR–

1 protein in CR–1 positive human

colorectal or embryonal carcinoma cells

by radioimmunoprecipitation analysis

and by ELISA.

6. Determine whether anti-CR–1

antibodies can be used for ICC on

formalin-fixed, paraffin embedded

tissues known for CR–1 expression.

7. Provide funds to support a

postdoctoral fellow and associated

expenses.

Criteria for choosing the collaborator

will include:

1. Experience in producing and

purifying recombinant proteins,

particularly growth factors or cytokines.

2. Experience in generating and

screening monoclonal antibodies.

3. Willingness to cooperate with the

NCI in the collection and evaluation of

data.

4. Willingness to cost share in

laboratory expenses.

5. And agreement to be bound by the

DHHS rules involving the use of human

and animal subjects and human tissues.

6. Provisions for equitable

distribution of patent rights to any

inventions. Generally, the rights of

ownership are retained by the

organization(s) which is/are the

employer(s) of the inventor. For

inventions made solely by the

collaborator’s employees, there shall be

a grant to the Government of a

nonexclusive, nontransferable,

irrevocable, paid up license to practice

the invention or have the invention

practiced throughout the world by or on

behalf of the Government for research or

other Government purposes. For

inventions not made solely by the

collaborator’s employees, there shall be

a grant to the collaborator of an option

to elect an exclusive or nonexclusive

commercialization license.

Dated: December 9, 1996.

Thomas Mays,

Director, Office of Technology Development,

National Cancer Institute, National Institutes

of Health.

[FR Doc. 97–1004 Filed 1–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Drug Abuse;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute on Drug Abuse

(NIDA) Initial Review Group and

Special Emphasis Panel meetings.

Purpose/Agenda: To review and evaluate

grant applications.

Name of Committee: Human Development

Research Subcommittee.

Date: February 11–12, 1997.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Kesinee Nimit, M.D.,

Scientific Review Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–22, Telephone (301) 443–9042.

Name of Committee: Neuropharmacology

Research Subcommittee.

Date: February 11–12, 1997.

Time: 8:30 a.m.

Place: Hyatt Regency Bethesda, One

Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Syed Husain, Ph.D,

Scientific Review, Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–22, Telephone (301) 443–2620.
Federal Register / Vol. 62, No. 10 / Wednesday, January 15, 1997 / Notices 2171

Name of Committee: Basic Behavioral

Science Research Subcommittee.

Date: February 11–13, 1997.

Time: 8:30 a.m.

Place: Sheraton Washington Hotel, 2660

Woodley Road at Connecticut, N.W.,

Washington, DC 20008.

Contact Person: William C. Grace, Ph.D.,

Scientific Review Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–22, Telephone (301) 443–9042.

Name of Committee: Epidemiology and

Prevention Research Subcommittee.

Date: February 11–13, 1997.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Raquel Crider, Ph.D.,

Scientific Review Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–22, Telephone (301) 443–9042.

Name of Committee: Molecular, Cellular

and Chemical Neurobiology Research

Subcommittee.

Date: February 12–14, 1997.

Time: 8:30 a.m.

Place: Ritz-Carlton Hotel at Pentagon City,

1250 South Hayes Street, Arlington, VA

22202.

Contact Person: Rita Liu, Ph.D., Scientific

Review Administrator, Office of Extramural

Program Review, National Institute on Drug

Abuse, 5600 Fishers Lane, Room 10–22,

Telephone (301) 443–2620.

Name of Committee: NIDA Special

Emphasis Panel.

Date: February 13, 1997.

Time: 2:00 p.m.

Place: Sheraton Washington Hotel, 2660

Woodley Road at Connecticut, N.W.,

Washington, DC 20008.

Contact Person: Khursheed Asghar, Ph.D.,

Scientific Review Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–42, Telephone (301) 443–2620.

Name of Committee: Neurophysiology and

Neuroanatomy Research Subcommittee.

Date: February 18–20, 1997.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Gamil Debbas, Ph.D.,

Scientific Review Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–22, Telephone (301) 443–2620.

The meetings will be closed in

accordance with provisions set forth in

sections 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. The applications and the

discussions could reveal confidential

trade secrets or commercial property

such as patentable material and

personal information concerning

individuals associated with the

applications, disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.277, Drug Abuse

Research Scientist Development and

Research Scientist Awards; 93.278, Drug

Abuse National Research Service Awards for

Research Training; 93.279, Drug Abuse

Research Programs.)

Dated: January 10, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–997 Filed 1–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Drug Abuse;

Notice of Meeting

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the National Advisory Council on Drug

Abuse, National Institute on Drug Abuse

(NIDA) on February 4–5, 1997, at the

National Institutes of Health, Building

31, 9000 Rockville Pike, Bethesda, MD

20892.

On February 4, from 9 a.m. to 4 p.m.,

the meeting will be held in Conference

Rooms 9 and 10. In accordance with

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

and sec. 10(d) of Public Law 92–463,

this portion of the meeting will be

closed to the public for the review,

discussion, and evaluation of grant

applications. These applications and the

discussions could reveal confidential

trade secrets or commercial property

such as patentable material and

personal information concerning

individuals associated with the

applications, disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

On February 5, from 9 a.m. to 5 p.m.,

the meeting will be held in Conference

Room 6. This portion of the meeting

will be open to the public for

announcements and reports of

administrative, legislative, and program

developments in the drug abuse field.

Attendance by the public will be limited

to space available.

A summary of the meeting and a

roster of committee members may be

obtained from Ms. Camilla L. Holland,

NIDA Committee Management Officer,

National Institutes of Health, Parklawn

Building, Room 10–42, 5600 Fishers

Lane, Rockville, Maryland 20857 (301/

443–2755).

Substantive program information may

be obtained from Ms. Eleanor C.

Friedenberg, Room 10–42, Parklawn

Building, 5600 Fishers Lane, Rockville,

Maryland 20857, (301/443/2755).

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Ms. Eleanor C. Friedenberg in

advance of the meeting.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.277, Drug Abuse

Research Scientist Development and

Research Scientist Awards; 93.278, Drug

Abuse National Research Service Awards for

Research Training; 93.279, Drug Abuse

Research Programs.)

Dated: January 10, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–998 Filed 1–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and

Infectious Diseases; Notice of Meeting:

Allergy, Immunology, and

Transplantation Research Committee

Pursuant to Public law 92–463, notice

is hereby given of the meeting of the

Allergy, Immunology, and

Transplantation Research Committee on

February 3–5, 1997, at the Belmont,

6555 Belmont Woods Road, Elkridge,

Maryland.

The meeting will be open to the

public from 8:30 to 9:30 a.m. on

February 3, to discuss administrative

details relating to committee business

and program review, and for a report

from the Director, Division of

Extramural Activities, which will

include a discussion of budgetary

matters. Attendance by the public will

be limited to space available.

In accordance with the provisions set

forth in Sections 552b(c)(4) and

552b(c)(6), Title 5, U.S.C. and sec. 10(d)

of Public law 92–463, the meeting will

be closed to the public for the review,

discussion, and evaluation of individual

grant applications and contract

proposals from 9:30 a.m. until recess on

February 3, from 9:30 a.m. until recess

on February 4, and from 9:30 a.m. until

adjournment on February 5. These

applications, proposals, and the

discussions could reveal confidential

trade secrets or commercial property

such as patentable material and

personal information concerning

individuals associated with the

applications and proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Ms. Claudia Goad, Committee

Management Officer, National Institute

of Allergy and Infectious Diseases, Solar

Building, Room 3C26, National

Institutes of Health, Bethesda, Maryland

20892, 301–496–7601, will provide a

summary of the meeting and a roster of

committee members upon request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should